Skip to content
← Index board

Health Optimization Index

TB-500 (Thymosin Beta-4 Fragment)

Nick’s assessment
Favorable
Research evidence
C, mixed evidence
Attention
8.1 / 100▼ Falling this week
7.5/ 10

BioHarmony score

TB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal healing in 6 of 10 RGN-259 subjects versus 1 of 8 placebo.

Read the full report Benefits, risks and practical guidance.

Read Nick’s assessment Why it earned this rating

TB-500 (Thymosin Beta-4 Fragment) is a 7.5–8.0/10 fit for people considering recovery repair, injury recovery, wound healing, or corneal healing, with the strongest case in acute, well-defined repair problems rather than broad wellness use. The human anchors sit on full-length thymosin beta-4, not the injected fragment, and they read as a trend rather than a win: Sosne 2023 missed its neurotrophic keratopathy primary endpoint at p=0.0656 in a trial stopped early at 18 patients, Sosne 2015 missed its dry-eye primary endpoints with significant secondaries, and the confirmatory European Phase 3 later missed as well. That mixed clinical record, plus strong preclinical and community recovery signal, is why TB-500 scores as a strong but caveated repair experiment. Treat TB-500 (Thymosin Beta-4 Fragment) as a tracked trial: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.

✅ Best for: Active adults with acute, well-defined tendon, ligament, muscle, or post-surgical recovery needs who already understand injectable peptide tradeoffs. TB-500 is most rational when conservative recovery is underway but too slow, when BPC-157 alone feels too narrow, and when the user can verify peptide quality. It is also worth tracking for people interested in full-length ophthalmic Tbeta4 research, where the human research is more direct than the musculoskeletal TB-500 story, even though its pivotal Phase 3 endpoints still missed. Pair it with progressive loading, protein, sleep, and clinician-aware recovery planning.

❌ Avoid if: You have active cancer, recent cancer, a strong family pattern of aggressive cancers, pregnancy, breastfeeding, or a WADA-tested sport context. Avoid TB-500 if you cannot verify source quality or sterile handling, because gray-market injection risk is separate from the molecule's theoretical profile. Avoid it if you need guideline-grade evidence before acting, because no large human musculoskeletal RCT exists. Also avoid using TB-500 to push through pain while ignoring diagnosis, imaging, surgical instructions, load management, or infection signs.

Share your experience

Your answers are optional and help other readers — they never change my score. How community input works.

Tried it in real life?

How would you assess it?

Favorable is the strongest rating, followed by Promising, then Experimental. Overhyped means the claims outrun the evidence or interest is fading.

Make a 12-month prediction Will it rise or fall in the Index?

Choose a direction and your confidence. Correct predictions earn leaderboard points.

Your 12-month call on TB-500 (Thymosin Beta-4 Fragment)
How sure are you?

Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →

Updated Sep 14, 2026 How the Index ranks →

Educational information, not medical advice. Ask a qualified clinician about risks and interactions. Independent ratings: no affiliate links, sponsored placements or paid rankings.